|
2 Companies |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
2 Trials |
|
5 News |
|
- | Dojolvi (triheptanoin) / Ultragenyx
Phase classification: Post Study Continuation of C7 for G1D (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=0, No Longer Available, Sponsor: Juan Pascual
Phase classification: P1 --> P=N/A
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) (clinicaltrials.gov) - Feb 16, 2019
P1/2, N=0, Withdrawn, Sponsor: Juan Pascual
Phase classification: P1 --> P=N/A N=50 --> 0 | Trial completion date: Jun 2019 --> Jun 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jun 2020
- Dojolvi (triheptanoin) / Ultragenyx
New trial: Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome (clinicaltrials.gov) - Nov 21, 2016
P=N/A, N=1, Enrolling by invitation, Sponsor: Amy Goldstein
- New trial, Compliance: Evaluation of Keyo in Children With Epilepsy (clinicaltrials.gov) - Sep 26, 2016
P=N/A, N=17, Completed, Sponsor: Vitaflo International, Ltd
- Dojolvi (triheptanoin) / Ultragenyx
New P1/2 trial: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) (clinicaltrials.gov) - Dec 25, 2013
P1/2, N=50, Not yet recruiting, Sponsor: Juan Pascual
- Dojolvi (triheptanoin) / Ultragenyx
New P1 trial: Post Study Continuation of C7 for G1D (clinicaltrials.gov) - Dec 19, 2013
P1, N=0, Available, Sponsor: Juan Pascual